Skip to main content
. Author manuscript; available in PMC: 2014 Jul 1.
Published in final edited form as: Arthritis Rheum. 2013 Jul;65(7):1865–1871. doi: 10.1002/art.37953

Table 4.

Effect of Change in 25 Hydroxy Vitamin D on SLE Disease Activity (Longitudinal Regression Models with One or Two-Slopes).

Disease Measure One-slope Model Model allowing slope to differ before and after 40 ng/mL
Slope1
(95% CI)		 P-value Slope1 over range
of 0–40 ng/mL
(95% CI)		 P-value Slope1 over range
of 40+ ng/mL
(95% CI)		 P-value
Physician Global Assessment −0.01 (−0.03, 0.01) 0.21 −0.04 (−0.08, −0.01) 0.026 0.01 (−0.02, 0.04) 0.50
SLEDAI-SLEDAI −0.02 (−0.11, 0.07) 0.65 −0.22 (−0.41, −0.02) 0.032 0.12 (−0.01, 0.24) 0.065
Log Urine Protein/Creatinine −0.02 (−0.03, −0.01) <0.0001 −0.03 (−0.05, −0.02) 0.0004 −0.01 (−0.01, 0.00) 0.24
Log HSCRP −0.02 (−0.09, 0.06) 0.64 −0.06 (−0.20, 0.09) 0.45 0.02 (−0.12, 0.15) 0.82
Log Anti-dsDNA 0.01 (−0.03, 0.04) 0.78 0.04 (−0.04, 0.11) 0.32 −0.02 (−0.07, 0.04) 0.55
1

Slopes are interpretable as difference in mean level of disease per 20ng/mL increase in vitamin D.